HOLON, Israel, May 15, 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a
clinical-stage cancer immunotherapy company and a pioneer in
computational target discovery, today announced the appointment of
David Silberman as its new Chief
Financial Officer effective August 15,
2024, taking over from Alberto
Sessa who will depart Compugen on the same day. David will
join Compugen from Oramed Pharmaceuticals Inc., where he served as
Chief Financial Officer.
"I am excited to welcome David to Compugen and believe his
experience and insights will make him a pivotal addition to our
team," said Anat Cohen-Dayag, Ph.D.,
President, and Chief Executive Officer of Compugen. "With
experience in the healthcare industry as a Chief Financial Officer
of a biotech company traded on the Nasdaq, along with his passion,
strategic thinking and commitment for results, I look forward to
working closely with David as part of Compugen's senior management
team to bring value to shareholders and to patients."
Mr. Silberman commented, "I am delighted to be joining Compugen
at this exciting time, with a planned catalyst rich 2024, multiple
proprietary innovative assets, validating partnerships with big
pharma and a computational discovery platform designed to enrich
the pipeline for long term sustainable growth. I look forward to
playing a meaningful role along with Anat and the Compugen team, to
ensure a strong financial position for our future, with the
ultimate goal of bringing new treatment options to cancer patients
worldwide."
Dr. Cohen-Dayag added, "I would also like to thank Alberto Sessa for his contribution to the
company. Since joining Compugen as Chief Financial Officer in 2022,
Alberto has been incredibly supportive in progressing our vision in
transforming patient lives by developing first-in-class
therapeutics based on our computational target discovery
platform."
David has more than 15 years of experience working in finance,
including 10 years of experience in the healthcare and biotech
industries. Prior to joining Oramed Pharmaceuticals as Chief
Financial Officer in 2021, David served as a Corporate Financial
Planning and Analysis Director and as Global Internal Audit Senior
Manager at Teva Pharmaceutical Industries Ltd. Earlier in his
career, David provided internal audit and risk management services
in the advisory department of Grant Thornton Fahn Kanne Control
Management and served in the audit department of KPMG. David holds
degrees in accounting and management from the French Ministry of
Higher Education and Research and is a certified public accountant
in Israel.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT
component is derived from Compugen's clinical stage anti-TIGIT
antibody, COM902, in Phase 3 development by AstraZeneca through a
license agreement for the development of bispecific and
multispecific antibodies. In addition, the Company's
therapeutic pipeline of early-stage immuno-oncology programs
consists of programs aiming to address various mechanisms of immune
resistance, of which the most advanced program, COM503, is in IND
enabling studies is licensed to Gilead. COM503 is a potential
first-in-class, high affinity antibody which blocks the interaction
between IL-18 binding protein and IL-18, thereby freeing natural
IL-18 in the tumor microenvironment to inhibit cancer growth.
Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Photo:
https://mma.prnewswire.com/media/2413436/Compugen_David_Silberman_CFO.jpg
Company contact:
Yvonne
Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
ir@cgen.com
+1 (628) 241-0071
View original content to download
multimedia:https://www.prnewswire.com/news-releases/compugen-appoints-david-silberman-as-chief-financial-officer-302146086.html
SOURCE Compugen Ltd.
